tbuckley/cabot-search huggingface dataset:
358P Major adverse cardiovascular event outcomes of adjuvant taxane + anthracycline versus taxane-based chemotherapy in older adults with triple-negative breast cancer: A SEER-Medicare study
Authors: S.C. Roy, S. Lakritz, A. Schreiber, E. Molina, C. Bradley, L. Kondapalli, J.R. Diamond
Journal: Annals of Oncology (2023)
1994P Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Authors: K. Rihawi, G. Lamberti, F. Riccardi, F. Mazzoni, A. Follador, A. Bonetti, D. Giardina, C. Genova, F. Bertolini, A. Frassoldati, M. Brighenti, I. Colantonio, G. Pasello, C. Ficorella, S. Cinieri, M. Tiseo, E. Andrini, M. Tognetto, L. Boni, A. Ardizzoni
Journal: Annals of Oncology (2023)
2322TiP SOUND: A phase II trial evaluating the efficacy of molecular profiling of circulating ± tumor tissue DNA for salvage-therapy matching in patients with advanced and refractory carcinoma
Authors: J.M. Riedl, S.M. Steinlechner, F. Moik, E. Heitzer, S. Jahn, S. Hasenleithner, B. Doleschal, L. Weiss, A. Seeber, H. Rumpold, T. Winder, R. Greil, P.J. Jost, G. Hoefler, M. Speicher, A. Gerger
Journal: Annals of Oncology (2023)
15P CBL E3 ubiquitin ligases are key inhibitory regulators in PD-1/LAG-3 co-signaling in human cancers, targeted through bispecific co-blockade
Authors: L. Chocarro, L. Fernández-Rubio, M.J. Garcia Granda, E. Blanco Palmeiro, A.I. Bocanegra Gondan, M. Echaide, M. Garnica, M. Zuazo, C. Johnston, C.J. Edwards, J. Leggs, A. Pierce, H. Arasanz, R. Vera, K. Ausin, E. Santamaría, J. Fernández-Irigoyen, G. Kochan, D. Escors
Journal: Annals of Oncology (2023)
2257P Stereotactic body radiation therapy and atezolizumab combination: Results of the international multi-centre SABR-PDL1 phase II trial colorectal cohort
Authors: A. Levy, R. Sun, M. Texier, M. Rodriguez, D. Morel, S. Racadot, S. Supiot, N. Magne, S. Cyrille, G. Louvel, J. Durand-Labrunie, L. Tselikas, A. Hollebecque, R. Bahleda, E. Deutsch
Journal: Annals of Oncology (2023)
1582P Gastroesophageal adenocarcinoma in young adults: Retrospective analysis of clinical and molecular features
Authors: D.A. Acosta Eyzaguirre, G. Castillo, S. Vega, S.A. Bueno Salazar, A. Carmona, A. Vázquez, S. Landolfi, S. Aguilar Izquierdo, A. Vivancos, M. Díez García, T. Macarulla
Journal: Annals of Oncology (2023)
1578P Effect of immune checkpoint inhibitors in metastatic gastric cancer: A real-world evidence study
Authors: F. Puccetti, E. Mazza, G. Hernández-Ibarburu, F. Rusconi, N. Liscia, L.A. Barbieri, E. Treppiedi, A. Cossu, R. Rosati, U. Elmore
Journal: Annals of Oncology (2023)
1574P Trastuzumab deruxtecan versus ramucirumab and paclitaxel as second-line therapy for patients with her2-positive gastric or gastro-esophageal junction adenocarcinoma: A propensity score matched comparison
Authors: R.H.A. Verhoeven, S. Kuijper, F. Lordick, M. Slingerland, A. Qin, H.W.M. van Laarhoven
Journal: Annals of Oncology (2023)
1528P A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Authors: D. Olson, E.E. Dumbrava, M. George, S. Saibil, A. Giordano, M. Gavrilliuc, B. Pieke, E. Lichtenstein, M. Apostolopoulou, K. Moss, D. Kirkwood, S. Dang, D. Adib, B.L. Schlechter
Journal: Annals of Oncology (2023)
2235P Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
Authors: P.P. Vitiello, R. Chilà, P. Battuello, V. Battaglieri, V. Amodio, G. Grasso, G. Rospo, S. Lamba, F. Pisati, B.J-C. Rousseau, L.A. Diaz, G. Crisafulli, F. Di Nicolantonio, G. Germano, A. Bardelli
Journal: Annals of Oncology (2023)
1560P Osemitamab (TST001): An ADCC enhanced humanized anti-CLDN18.2 mab, demonstrated improved efficacy in combination with anti-PD-L1/PD-1 mab and oxaliplatin/5-FU in preclinical tumor models
Authors: X. Qian, F. Teng, H. Guo, X. Yao, L. Shi, Y. Wu, D. Zhao, Y. Gu
Journal: Annals of Oncology (2023)
1572P Impact of HER2 and PD-L1 co-expression in Claudin18.2 positive resectable gastroesophageal cancers
Authors: A. Cammarota, G. Devonshire, A. Miremadi, A. Ustaoglu, B. Filippi, J.L. Zhuang, S. Zamani, N. Masqué-Soler, L. Rimassa, R.C. Fitzgerald, E. Smyth
Journal: Annals of Oncology (2023)
2261P A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2- breast cancer patients
Authors: N. Dandachi, R. Graf, L. Pancheri, N. Dobrić, E.V. Klocker, C. Suppan, P.J. Jost, E. Heitzer, M. Balic
Journal: Annals of Oncology (2023)
2316P Integrating comprehensive cancer genome profiling into clinical practice in an Italian referral center: Results of the first year of the fpg500 programme
Authors: C. Nero, S. Duranti, F. Giacomini, I. Marino, A. Minucci, M. De Bonis, L. Giacò, A. Preziosi, D. Giannarelli, F. Camarda, A. Piermattei, A. Panfili, T. Pasciuto, D. Lorusso, L. Salvatore, N. Normanno, E. Bria, A. Vitale, G. Tortora, G. Scambia
Journal: Annals of Oncology (2023)
1562P Claudin 18.2 expression in resected gastric cancer
Authors: M. Furuta, Y. Hiroshima, S. Sato, M. Oonishi, T. Hama, K. Furusawa, K. Hayashi, Y. Inokuchi, M. Tanabe, J. Morita, S. Nagasawa, K. Kanematsu, T. Yamada, T. Ogata, T. Oshima, Y. Miyagi, T. Yokose, N. Machida, J. Furuse
Journal: Annals of Oncology (2023)
1539P Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer (GC/EGJC): Preliminary results of a phase II, single-arm trial
Authors: F. Wang, C. Zhao, J. Xia, Z. Liu, X. Meng, Z. Shan, J. Jiang, X. Liu, H. Li, J. Sun, C. Ding, H. Zhang, W. Liang
Journal: Annals of Oncology (2023)
115P Inhibition of KLF5 reduces tumor growth and sensitizes to chemotherapy-induced cell death in experimental models of cholangiocarcinoma
Authors: A. Landa Magdalena, P.M. Rodrigues, O. Erice, N.A. Paiva, M.G. Fernandez-Barrena, P. Olaizola, A. Lapitz, C.J. O'Rourke, J.B. Andersen, D.F. Calvisi, M. Azkargorta, F. Elortza, I. Goicoechea, C.H. Lawrie, L. Bujanda, M.J. Perugorria, J.M. Bañales
Journal: Annals of Oncology (2023)
2252P KRAS G12C inhibition using MRTX849: A novel radio-sensitizing partner
Authors: M. Milic, P-A. Laurent, C. Quevrin, L. Meziani, D. Morel, N. Signolle, C. Clémenson, A. Levy, M. Mondini, E. Deutsch
Journal: Annals of Oncology (2023)
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients
Authors: G. Mazzaschi, E. Cardinale, M. Pluchino, G. Monica, B. Lorusso, S. D'Agnelli, F. Trentini, P. Tamarozzi, L. Moron Dalla Tor, M. Verzè, R. Minari, P. Bordi, F. Perrone, A. Leonetti, L. Gnetti, G. Roti, F. Quaini, N. Sverzellati, M. Tiseo
Journal: Annals of Oncology (2023)
2300P Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
Authors: J.E. Rodriguez, F-X. Danlos, A. Larive, A. Marabelle, M. Frelaut, M. Tagliamento, M. Aldea, B. Besse, J. Baptiste Micol, S. Ponce Aix, C. Marzac, N. Chaput-Gras, C. Massard, C. Baldini
Journal: Annals of Oncology (2023)
2022P ALBA project: Prognostic impact of laterality in small cell lung cancer
Authors: L. Landi, B. Resuli, A. D'Incecco, A. Tufman, K. Cannita, G. Minuti, D. Kauffmann-Guerrero, A. Laudisi, J. Behr, S. Buglioni, A. Faggiano, None G.R. quaglione, T.A. Bolt, B. Marcozzi, S. Bellino, F.L. Cecere, G. Ciliberto, N. Reinmuth, F. Cappuzzo, A. La Salvia
Journal: Annals of Oncology (2023)
2010P Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Authors: S. Perimbeti, M. Khorrami, V.S. Viswanathan, M. ZIa, A. Gupta, C.L. Roche, C. Barrera, None H. trivedi, M. Behera, K. Higgins, P. Jain, A. Madabhushi
Journal: Annals of Oncology (2023)
33P Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Authors: K. Cortese, O. Garrone, M.C. Gagliani, G. Bellese, P. Arnaldi, A. Abbona, M. Paccagnella, F. Ruatta, M.C. Merlano, P. Castagnola
Journal: Annals of Oncology (2023)
112P Clinical, genomic and transcriptomic characteristics of young-onset biliary tract cancers
Authors: T. Pudlarz, L. Antoun, A. Rousseau, R. Nicolle, M. Gelli, E. Fernandez de Sevilla, S. Cosconea, L. Tselikas, R. Barbe, A. Turpin, M. Deloger, A. Italiano, M. Valery, A.A. Tarabay, V. Boige, D. Malka, C. Smolenschi, A. Hollebecque, M.P. Ducreux, A. Boileve
Journal: Annals of Oncology (2023)
2354P Computational pathology-derived features capture varied epithelial-mesenchymal transition (EMT) states
Authors: H. Levine, C. Kirkup, S. Vilchez, S. Srinivasan, M. Lin, J. Abel, M. Drage, J. Conway, A. Khosla, A. Taylor-Weiner
Journal: Annals of Oncology (2023)
1547P SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer
Authors: C. Inagaki, R. Matoba, H. Iijuma, J. Hihara, H. Yasui, M. Tsuda, T. Suzuki, A. Makiyama, H. Yabusaki, J. Matsuyama, M. Takahashi, Y. Kito, Y. Akamaru, A. Ishiguro, R. Kawabata, Y. Sakamoto, E. Inoue, W. Ichikawa, M. Fujii, Y. Sunakawa
Journal: Annals of Oncology (2023)
2001P Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Authors: V. Longo, F. Vitiello, F. Spinnato, F. Ambrosio, T. Del Giudice, M.C.I. Sergi, F. Casaluce, M. Montrone, M. Gilli, M.L. Reale, R. Di Liello, A. Russo, V. Sforza, V. Gristina, A. Servetto, A. Cristofano, G. Viscardi, A. Marchese, D. Galetta, C.M. Della Corte
Journal: Annals of Oncology (2023)
1554P Clinical Impact of ERBB2 copy number and tumor mutation burden (TMB) in patients with HER2- positive advanced gastric cancer treated by nivolumab (N-mab) plus trastuzumab (T-mab) and standard chemotherapy
Authors: H. Shoji, T. Wakatsuki, D. Takahari, N. Yamamoto, A. Ooki, K. Chin, N. Kurihara, K. Kiyotani, T. Mashima, M. Ogura, I. Nakayama, K. Minashi, H. Hara, E. Shinozaki, N. Ishizuka, S. Kitano, H. Seimiya, K. Takeuchi, N. Boku, K. Yamaguchi
Journal: Annals of Oncology (2023)
2241P A novel 89Zr-anti-PD-1 immuno-PET-CT may predict response to PD-1 inhibitors and improve response assessment in a lung cancer murine model receiving immunotherapy
Authors: A. Puyalto, M. Rodríguez-Remírez, I. López, J.A. Simon, M. Ecay, M. Collantes, A. Vilalta, A. Francisco-Cruz, J.L. Solórzano, I. Peñuelas, D. Ajona, I. Gil Bazo
Journal: Annals of Oncology (2023)
1569P The CODRP model for predicting drug sensitivity in patient-derived 3D gastric cancer cells
Authors: D.W. Lee, I.H. Kim, J. Lee, S.H. Yun, B. Ku, S. Lee, M. Yoo, D. Seol, T-K. Lee, E. Lee, D-Y. Hwang, S.H. Kang, Y.S. Park, J-W. Kim, J.W. Kim, S-H. Ahn, K-W. Lee, H-H. Kim, H. Oh, Y-S. Suh
Journal: Annals of Oncology (2023)
1585P The impact of platinum-induced peripheral neuropathy (PN) in first-line treatment on PN and efficacy in second-line paclitaxel (PTX)-based chemotherapy for unresectable advanced gastric cancer (AGC): A prospective observational multicenter study - IVY study
Authors: Y. Kono, H. Tanioka, Y. Kito, T. Ando, Y. Negoro, T. Abe, H. Kuramochi, S. Boku, T. Mannami, J. Nasu, M. Inoue, M. Nakamura, Y. Okita, Y. Shindo, T. Maeda, Y. Shinohara, S. Yano, M. Okawaki, T. Nagasaka
Journal: Annals of Oncology (2023)
2008P Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Authors: F.A. Duarte, R. Dienstmann, P. Diniz, M. Costa e Silva, G.G. Viana Veloso, G. Arcanjo, R. Paes, T. Montella, H. Cuba, E. Macuzo, B.L. Ferrari, C.G.M. Ferreira
Journal: Annals of Oncology (2023)
2002P A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Authors: M. Porte, A. Vaudron, P. Crequit, None T. chatellier, C. Fronteau, J. Raimbourg, T. Goronflot, J. Bennouna, E. Pons-Tostivint
Journal: Annals of Oncology (2023)
99P Bevacizumab plus erlotinib maintenance versus observation in advanced biliary tract cancers: Results from the phase II component of a prospective integrated phase II-phase III parallel design superiority clinical trial (BEER-BTC study)
Authors: A. Ramaswamy, V.S. Ostwal, P.G. Bhargava, S. Srinivas, A. Kapoor, M. Goel, S. Patkar, A. Gupta, B. Sansar, V. Kapu, B. Mishra, A. Sharma, R.K. Rai, P. Gupta, S. Mandavkar, M. Parulekar, D. Chaugule, N. Aier, R. Patil, C. Nashikkar
Journal: Annals of Oncology (2023)
2250P Exploring tumor microenvironment in lung cancer through patient-derived 3D models
Authors: N. Juciute, L.A. Boada-Acosta, S. Torres-Martínez, E. Escorihuela, E. Munera Maravilla, M. Mosqueda-Frometa, M. Castellote-Borrell, A. Rodriguez, N. Miranda, L. Roz, L. Navarro-Cerveró, B. Blanco, J. Guasch, R. Guijarro, E. Pastor-Martinez, S. Calabuig Fariñas, C. Camps Herrero, E. Jantus Lewintre
Journal: Annals of Oncology (2023)
2239P Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types
Authors: E. Segui Solis, T. Pascual, E. Sanfeliu Torres, B. Gonzalez-farre, F. Brasó-Maristany, X. González Farre, F. Salvador, E. Felip, E. Garralda, L. Paz-Ares, M.J. Otero, R. Mesia Nin, A.M. Arance Fernandez, A. Cervantes, J. Martin-Liberal, J. Gavilá-Gregori, K. Amillano Parraga, F.E. Racca, J. Tabernero, A. Prat
Journal: Annals of Oncology (2023)
2237P Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial
Authors: N. Huyghe, E. Benidovskaya, T. Masoodi, J. Carrasco, A. De Cuyper, I. Sinapi, F. Vempalli, E. Verstraelen, P. Goffette, B. Ghaye, M. Papier, D. Bedognetti, A. van Maanen, M-L. Castella, J. Galon, M. van den Eynde
Journal: Annals of Oncology (2023)
95MO Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma
Authors: M. Javle, L.A. Kankeu Fonkoua, A. Mahipal, C-Y. Liao, C. Fountzilas, D. Li, M.S. Pelster, S. Goel, P. Peng, C. Sun, H. Wang, K. Hennessy, X. Fu, L. Neo, Y. Shan, P. Huang, D. Wu, F. Wu, J. Fan, S.A. Piha-Paul
Journal: Annals of Oncology (2023)
2019P Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Authors: M. Esteban García, E. Jimenez Aguilar, A.M. González López, T. Robles Bermejo, Y. Pernas Sánchez, R. Avilés Peña, E. Perez Fernandez, S. Adeva Antona, J.C. Cámara Vicario, C. Olier Gárate, S. Hernando Polo, A. Hurtado Nuño, D. Moreno Muñoz, X. Mielgo Rubio
Journal: Annals of Oncology (2023)
94MO Advanced extrahepatic cholangiocarcinoma: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials
Authors: A. Lamarca, P.J. Ross, H.S. Wasan, R. Hubner, M.G. McNamara, A. Lopes, D. Palmer, J.W. Valle, J.A. Bridgewater
Journal: Annals of Oncology (2023)
2352P Sex-based differences in genomic alterations and biomarkers in anal squamous cell carcinoma (ASCC)
Authors: S. Cereda, M. Ronzoni, B. Kaplan, J. Suh, S. Sivakumar, S. Foti, M. Mariani, N. Liscia, F. Vitiello, G. Basile, M. Bandini, E. Mazza, A. Necchi, S. Cascinu
Journal: Annals of Oncology (2023)
114P Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers
Authors: G. King, S.A. Cohen, E.G. Chiorean, W.P. Harris, R. Yeung, J. Park, D.B. Zhen, A.L. Coveler, A. Diehl, R. Safyan, A. Jurdi, C. Brdiges
Journal: Annals of Oncology (2023)
1992P A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Authors: Y. Cheng, Z. Qin, X. Meng, F. Xu, Y. Wang, Y. Yao, J. Fang, Y. Zhao
Journal: Annals of Oncology (2023)
123P Artificial intelligence (AI)-powered analysis of human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TILs) in advanced biliary tract cancer (BTC)
Authors: G. Kim, C. Kim, B. Kang, S. Shin, T. Lee, S. Song, S. Kim, M. Mostafavi, H. Song, S. Pereira, H. Chon
Journal: Annals of Oncology (2023)
2339P Clinical and genomic correlates of plasma circulating tumor DNA (ctDNA) tumor fraction (TF) in patients with advanced NSCLC
Authors: None F.G. dall'Olio, D. Vasseur, A. Mamann, C.A. Garcia, K. Beshiri, A. Marinello, M. Tagliamento, M.R. Ghigna, M. Aldea, D. Planchard, L. Pasquina, F. Barlesi, A. Italiano, R. Madison, G. Oxnard, B. Besse
Journal: Annals of Oncology (2023)
129P Prognostic factors associated with survival in resected biliary tract cancers: A multicentre Italian experience
Authors: M. Ghidini, M. Paccagnella, M. Salati, F. Bergamo, M. Ratti, B. Galassi, O. Garrone, M. Rovatti, L. Caccamo, E. Gringeri, A. Zerbi, None G. Torzilli, S. Bozzarelli, L. Rimassa
Journal: Annals of Oncology (2023)
110P Detection of HER2 overexpression in biliary tract cancers: Comparison of AmoyDx® HER-2 (29D8) assay with ventana PATHWAY anti-HER-2/neu (4B5) assay
Authors: H. Dong, W. Su, H. Lu, Z. Liu, Z. Tang, Z. Huang, L. Ruan, C. Zhu
Journal: Annals of Oncology (2023)
118P Artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker for anti-PD-1 in advanced biliary tract cancer (BTC)
Authors: Y. Bang, C-K. Lee, K. Bang, H-D. Kim, K-P. Kim, J.H. Jeong, B-Y. Ryoo, C. Oum, S. Kim, Y. Lim, G. Park, C-Y. Ock, J.H. Shin, C. Yoo
Journal: Annals of Oncology (2023)
102P Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study
Authors: A.R. He, M. Bouattour, V.G. Gupta, L. Evesque, D.B. Zhen, J.O. Park, A. Sookprasert, A. Salvatierra, G.M. Vaccaro, S.C. Oh, S.A. Ostoich, T. Satoh, M. Żotkiewicz, N. Rokutanda, H. Kim, D-Y. Oh
Journal: Annals of Oncology (2023)
107P Comprehensive genomic profiling of “The German-registry of incidental gallbladder carcinoma” cases
Authors: N.B. Agaoglu, L. Kochen, D.W. Müller, D. Vortmeyer, T. Habibzada, S-E. Al-Batran, T.O. Goetze
Journal: Annals of Oncology (2023)
122P Largest examination of cholangiocarcinoma (CCA) patients (pts) treated with novel targeted therapies after extended molecular profiling on liquid biopsies
Authors: U. Mahmood, E. Muhamad Faizul, S. Howlett, D. Hochhauser, K-K. Shiu, J.A. Bridgewater, K.H. Khan
Journal: Annals of Oncology (2023)
103P Individual patient data (IPD) meta-analysis of randomised trials to compare efficacy of second-line fluoropyrimidine-based chemotherapy in advanced biliary tract cancer (BTC)
Authors: J. Hyung, M. Kang, I. Kim, K-P. Kim, B-Y. Ryoo, J. Cheon, H. Ryu, J.S. Lee, G.K. Abou-Alfa, J-W. Kim, I. Choi, J.H. Park, J.W. Kim, C. Yoo
Journal: Annals of Oncology (2023)
2357P TRX-221, a 4th generation, mutant-selective, and CNS-active EGFR inhibitor with robust antitumor activity in osimertinib-resistant tumor models harboring C797S mutation
Authors: S. Lim, S. Choi, J. Lee, S. Kim, E. Choi, S. Lee, K. Chun, K. Lee
Journal: Annals of Oncology (2023)
96P Comparing the outcome of doublet therapy (gemcitabine and cisplatin) with triplet therapy (gemcitabine and cisplatin, nab paclitaxel) in locally advanced or metastatic gall bladder cancer patients an open label randomised control trial
Authors: C. Khatri, R. Rattan, A. Narwariya, P.K. Das, J. Patowary
Journal: Annals of Oncology (2023)
98P Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: Extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 study
Authors: S. Qin, J-Q. Cai, E. Li, B. Xing, L. Zhao, C. Dai, J. Li, Y. Shen, Z. Chen, L. Liu, Z. Lu, A. Zang, Y. Bai, H. Liang, J. Liang, X. Liu, J. Wang, M-H. Chen, R. Miao, X. Qu
Journal: Annals of Oncology (2023)
2231O Pan-cancer assessment of the impact of intronic variants on cancer development and progression
Authors: A. Safonov, M. Mehine, O. Ceyhan-Birsoy, D. Brown, C. Bandlamudi, A. Forbes, A. Gazzo, P. Selenica, R. Shen, E. Khurana, L. Norton, D. Solit, S. Chandarlapaty, P. Razavi, M. Robson, B. Weigelt, M. Berger, M. Ladanyi, J.S. Reis-Filho, D. Mandelker
Journal: Annals of Oncology (2023)
1999P IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Authors: S. Popat, N. Girard, S. Shoshkova, G. Kok, J.L. Perez Gracia
Journal: Annals of Oncology (2023)
2026P Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Authors: L. Falchero, L. Moreau, M. Fore, R. Corre, E. Auvray, E. Redureau, H. Francois, C. Dayen, C. Rizzo, S. Thierry, M. Tiercin, B. Jarjour, P. Beynel, C. Dujon, H. Ghalloussi-Tebai, A. Cortot, H. Morel, D. Debieuvre
Journal: Annals of Oncology (2023)
2251P The genomic landscape of radiotherapy-induced breast angiosarcoma: An alleanza contro il cancro (ACC) initiative for an unmet need in rare tumors
Authors: L. Ferrando, E. Nano, A. Garuti, N. Gilardi, M. Maetens, M. Stabile, A. Vingiani, G. Frige, M. Lambertini, F. Grillo, G. Floris, G. Pruneri, C. Desmedt, L. Mazzarella, A. Ballestrero, G. Zoppoli
Journal: Annals of Oncology (2023)
2016P The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Authors: A. Cebrian, L. Del Puerto-Nevado, J.M. Corral, M. Cedeño, A. Rio-Vilariño, I. Mahillo-Fernandez, C. Galeano, N. Baños, J. Garcia-Foncillas, M. Dómine
Journal: Annals of Oncology (2023)
2020P Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Authors: G. Pasello, L. Urso, I. Cavallari, M. Lorenzi, M.V. Resi, S. Giunco, G. Pigato, E. Sharova, E. Sharova, A. Ferro, A. Dal Maso, S. Frega, L. Bonanno, S. Indraccolo, A. De Rossi, D.M. D'Agostino, V. Ciminale, V. Guarneri
Journal: Annals of Oncology (2023)
2234P Local immune-related adverse events (irAEs) are more common in tumor-bearing organs
Authors: S.M. Blum, B. Ouyang, L. Zubiri, D. Leonard, J. Barth, D.A. Zlotoff, N.P. Smith, D.P. Lawrence, D. Juric, J.R. Stone, M. Dougan, A-C. Villani, K.L. Reynolds, M. Mino-Kenudson, R.J. Sullivan
Journal: Annals of Oncology (2023)
119P Management of biliary tract cancers in older patients: A French multicenter cohort study
Authors: M. Valery, J. Edeline, J. Henriques, L. Antoun, H. Bourien, A. Lebeaud, N. Fares, C. Tournigand, T. Lecomte, D. Tougeron, V. Hautefeuille, A. Vienot, N. Williet, J-B. Bachet, D. Malka, C. Smolenschi, A. Hollebecque, J-R. Paccard, A. Turpin, A. Boileve
Journal: Annals of Oncology (2023)
105P A phase II study of SHR-1316 plus IBI310 in patients with advanced intrahepatic cholangiocarcinoma after failure of first-line therapy
Authors: J. Fan, J. Zhou, G. SHI, X. Huang, X. Guo, J. Lu, F. Liang, Y. Chen, D. Wu, Y. Ji, Y. Hou, X. Meng, Z. Tang, X. Huang, Q. Ye, S. Qiu, Q. Gao, Y. Shi, H. Sun, H. Li
Journal: Annals of Oncology (2023)
2240P Novel genetic markers associated with immune checkpoint inhibitor induced immune-related adverse events
Authors: I.S. Chin, L. Mcdonald, A.C. Gault, M. Harland, C. Jolly, A. Khan, O. Tong, M. Sivaswami, R.A. Watson, A. González-Neira, S. Papa, A.C. Olsson-Brown, K. Williams, A. Pratt, J. Newton-Bishop, A.P. Cope, G. Middleton, B.P. Fairfax, C. Palles
Journal: Annals of Oncology (2023)
128P Biliary tract cancers: Epidemiological and prognosis trends of Latin American population
Authors: M.D.C. Diaz Romero, G. Calderillo Ruiz, E. García, B. Carbajal, D.A.G. Padilla, G.E. Trejo-Duran, P. Morales Esponda Mendoza, D.L. Guerra Figueroa
Journal: Annals of Oncology (2023)
2017P Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Authors: M. Urbini, M. Canale, M. Flospergher, K. Andrikou, P. Cravero, L. Pasini, A. Dubini, R. Panzacchi, C. Bennati, G. Rossi, D. Tassinari, M. Valli, A. Delmonte, L. Crinò, P. Ulivi
Journal: Annals of Oncology (2023)